A living hydrogel-based wound dressing containing essential oils and probiotics and carrying oxygen
The hydrogel-based wound dressing with integrated oxygen carriers and pH-dependent probiotic metabolites addresses the challenge of ineffective biomolecule release in existing dressings, enhancing wound healing and reducing infection risk and costs.
Patent Information
- Application Number
- PCT/TR2026/050429
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2026-04-22
- Publication Date
- 2026-11-12
AI Technical Summary
Existing wound dressings fail to provide simultaneous, prolonged, and controlled release of oxygen and probiotic metabolites, leading to ineffective treatment of chronic wounds, especially in hypoxic and acidic environments, and frequent changes increase infection risk and treatment costs.
A hydrogel-based wound dressing incorporating perfluorocarbon-based oxygen carriers, essential oils, and pH-dependent probiotic metabolites, encapsulated with organosilica and alginate, for sustained release of oxygen and probiotic metabolites, creating an active antibacterial environment.
The dressing reduces infection risk, accelerates wound healing, and decreases treatment frequency and costs by providing prolonged, controlled release of biomolecules, promoting healthy cell vitality and proliferation.
Smart Images

Figure 00000019_0000 
Figure 00000019_0001 
Figure 00000020_0000
Abstract
Description
[0001] DESCRIPTION
[0002] A LIVING HYDROGEL-BASED WOUND DRESSING CONTAINING ESSENTIAL OILS AND PROBIOTICS AND CARRYING OXYGEN
[0003] Technical Field
[0004] The invention relates to a living hydrogel-based wound dressing containing essential oils and beneficial probiotic metabolites, which possesses anti-inflammatory and antibacterial properties and delivers oxygen, for use in the treatment of chronic wounds, as well as the method for producing said wound dressing.
[0005] State of the Art
[0006] Wound dressings are biomaterials that protect injured tissues, reduce the risk of infection and accelerate the healing process. The most commonly preferred wound dressings today are gauze dressings containing antiseptics, hydrogel-based dressings and wound dressings containing antibacterial agents. Wound dressings used in the present art have functions such as providing moisture balance, preventing infection, and promoting tissue regeneration. However, these wound dressings are insufficient to release biomolecules in a prolonged and controlled manner and their effectiveness is limited, particularly in hypoxic and acidic environments.
[0007] In the present art, the application of oxygen, essential oils and probiotic metabolites to promote wound healing is performed individually. However, in these methods, the release times of these biomolecules cannot be controlled and their simultaneous delivery to the desired tissue cannot be ensured. Existing biomaterials that provide oxygen release usually provide an immediate and short-term release of oxygen, whereas essential oils and probiotic metabolites are administered independently, which limits their effectiveness. In particular, in pathological conditions such as inflammation, cancer, infection, and diabetic ulcers — which are characterized by hypoxic and acidic conditions — the inability to release oxygen and therapeutic biomolecules in a controlled, sustained, and targeted manner leads to a slow progression of the treatment process and a reduction in its efficacy.
[0008] Since the wound dressings or topical treatment materials in the state of the art have to be changed frequently, the healing tissue layer can be damaged with each change and this causes discomfort for patients. The need for frequent replacement increases treatment costs and alsoincreases the risk of infection. In addition, high doses of oxygen and essential oils can cause toxic effects on healthy cells, while the unnecessary release of probiotic metabolites in non-acidic environments reduces their beneficial effects. These shortcomings make it difficult to optimize treatment processes and delay healing, especially for chronic wounds or infected tissues.
[0009] Existing systems are unable to provide simultaneous and prolonged release of oxygen and other bioactive components, and they also do not include a pH-sensitive probiotic metabolite release mechanism. This makes it difficult to correct the hypoxic and acidic microenvironment in healing diseased tissues such as inflammation, cancer and infection. More specifically, in a hypoxic and acidic microenvironment, cell regeneration and tissue repair can be delayed due to insufficient oxygen supply, which can make healing of chronic wounds more difficult. At the same time, irregular or short-term release of biomolecules with antibacterial and antiinflammatory properties can lead to an increased risk of infection and a failure to control inflammation.
[0010] Document KR20210077069A in the state of the art relates to an anti-inflammatory cosmetic composition and the preparation method thereof. In said invention, the release of oxygen and the release of anti-inflammatory, antibacterial and anticarcinogenic metabolites, which are necessary to accelerate wound healing in hypoxic and inflammatory wound tissue and to provide longer treatment, cannot be done depending on pH and the dose of metabolite release cannot be realized according to the condition of the wound.
[0011] In another state of the art, document CN116510069A relates to a hydrogel prepared by mixing GelMA solution and lactobacillus casei bacterial culture and subsequently gelling the mixture. In the present invention, it is not possible to achieve pH-sensitive release of anti-inflammatory, antibacterial, and anticarcinogenic metabolites in conjunction with controlled oxygen release to support wound healing in hypoxic and inflammatory wound tissue. This leads to a lack of dosage adjustment according to the physiological conditions of the wound and limited treatment efficacy.
[0012] In order to overcome the disadvantages mentioned in the state of the art and above, it is necessary to develop new wound dressings that provide oxygen and controlled pH-dependentco-distribution of anti-inflammatory and anti-bacterial essential oils and beneficial probiotic metabolites within the same biomaterial.
[0013] Summary of the Invention
[0014] In order to eliminate the above-mentioned disadvantages and provide new advantages to the relevant technical field, the invention relates to an anti-inflammatory and anti-bacterial viable hydrogel-based wound dressing containing essential oil and beneficial probiotic metabolites and carrying oxygen for use in chronic wound treatments, and to a production method of said wound dressing.
[0015] The invention relates to a hydrogel-based wound dressing that provides a prolonged and controlled release of oxygen, essential oil and pH-dependent probiotic metabolites. Thanks to the synergistic effect of the concurrent (simultaneous) release of oxygen, essential oils, and probiotic metabolites, it prevents bacterial growth on and around the wound site and simultaneously inhibits inflammation, cancer, and infection which are under hypoxic and acidic conditions by enabling oxygen and natural medicine therapy, faster healing of chronic wounds and damaged tissues by promoting healthy cell vitality and proliferation particularly in pathological conditions where hypoxia and acidic pH are active or triggered (inflammation, cancer, infection, diabetic ulcers, burns),
[0016] The invention provides for prolonged and slow release of oxygen and essential oils and simultaneous pH-dependent release of probiotic metabolites, thereby ensuring the enhancement of treatment efficacy. In current techniques, oxygen and essential oils are often released instantaneously and erratically, which causes toxic effects on healthy cells. By enabling the slow and prolonged release of these biomolecules, the invention prevents immediate toxic effects on cells and creates a sustainable effect in the treatment process. Essential oil release is 14 micro grams of essential oil after 5 days and oxygen release is 11.5% oxygen for 15 days. It also activates probiotic metabolites that are released in a pH-dependent manner only in diseased and acidic environments. In this way, healthy tissues are not unnecessarily exposed to biomolecules and the treatment is only effective in the areas where it is needed.
[0017] The wound dressing subject to the invention reduces the risk of infection. Bacterial growth in wound areas increases the risk of infection and delays the healing process. Existing wounddressings generally provide passive protection and do not prevent the proliferation of bacteria. Whereas, the invention creates an active antibacterial environment in the wound area by releasing antibacterial essential oils and probiotic metabolites in a controlled manner. Thus, it prevents bacteria from colonizing the wound surface, reducing the risk of infection and promoting wound healing.
[0018] The invention is a single system capable of prolonged release of essential oil, oxygen and pH-dependent probiotic metabolite with pH-dependent anti-inflammatory, antibacterial and anticarcinogenic effects and combines the units in the same biomaterial. Consequently, as the release of these biomolecules is spread out over time, the direct impact of potentially harmful levels of oxygen, essential oils, and metabolites on healthy cells is reduced, and the antiinflammatory and antibacterial effects of these biomolecules are sustained over the long term. As a result, the frequency of changing wound dressings made from these materials is reduced, as are issues such as damage to the healing wound bed caused by frequent dressing changes and impaired patient comfort; consequently, this leads to a reduction in treatment costs. In addition, economic benefits and savings are achieved for both patients and healthcare systems through reduced material use, lower infection rates and faster recovery.
[0019] The prolonged and controlled release of oxygen and essential oils provided by the invention supports the survival of healthy cells and promotes cell proliferation through the action of probiotic metabolites. In this way, new tissue formation is accelerated and chronic wounds heal faster.
[0020] The hydrogel-based nature of the invention enables the development of topically applicable gels and wound dressings. Hydrogels promote cell regeneration by maintaining moisture balance in the wound area, while the biomolecules contained in the invention make the treatment process even more effective. This multifunctional structure enables the development of specialized treatment approaches for various wound types, such as bums, diabetic ulcers, cancer-related wounds, and infected wounds.
[0021] The invention is capable of pH-dependent release of anti-inflammatory, antibacterial and anticarcinogenic metabolites released by lactic acid bacteria and thus can dose the release of metabolites according to the condition of the wound. In doing so, it also provides long-term release of oxygen and essential oils and ensures the strengthening of the effect of metabolites.Description of the Drawings
[0022] Fig. 1. A representative graphical view showing the release of tea tree oil from a hydrogel / alginate containing tea tree oil (Mixture 2) and from a hydrogel containing PMOF and tea tree oil (Mixture 4).
[0023] Fig. 2. A representative graphical view of alginate (Mixture 1) and alginate containing PMOF (Mixture 3) showing oxygen release in hypoxic environment.
[0024] Fig. 3. A representative graphical view showing the viability of fibroblast cells in the presence of Mixture 1, Mixture 2, Mixture 3, Mixture 4, and Mixture 5 and after 5 days of incubation in hypoxic medium.
[0025] Fig. 4. A representative graphical view showing the effect of tea tree oil in different ratios in Mixture 2 and Mixture 4 on E. coli bacterium.
[0026] Fig. 5. A representative graphical view showing the effect of tea tree oil in different ratios in Mixture 2 and Mixture 4 on and S. aureus bacterium.
[0027] Fig. 6. A representative view of the pH-dependent cumulative lactic acid release graph of probiotics in mixture B over an 8-day period.
[0028] Fig. 7. A representative graphical view showing the number of live probiotics in Alg-LacPMO-NH2 (Mixture B) andLacPMO-NH2 (Mixture A) media, based on CFU testing.
[0029] Fig. 8. A representative graphical view showing the release of lactic acid by probiotics in Mixture A and Mixture B over a 7-day period.
[0030] Fig. 9. A representative graphical view showing the number of probiotics coated with Alg-LacPMO-NH2 in tea tree medium (Mixture C) and live probiotics in the probiotics control group medium (Mixture D), based on the CFU test.
[0031] Fig. 10. Lactic acid release graph of probiotics coated with Alg-LacPMO-NH2 (Mixture C) and probiotics control group (Mixture D) in tea tree medium for 1 day.
[0032] Fig. 11. A representative graph showing the effects of gelatin methacrylate (GelMA) (Mixture E) and the wound dressing (GelMA-CAP) (Mixture F) subject to the invention on healthy (fibroblast) and cancer (Malme-3M) cells under hypoxic conditions.
[0033] Detailed Description of the Invention
[0034] The example embodiments are described in more detail below with reference to the accompanying descriptions. Furthermore, the embodiments can be established in different forms and should not be interpreted as being limited to the embodiments specified herein.Rather, these example embodiments are provided so that this description will be thorough, and will fully convey the scope to those skilled in the art.
[0035] The invention relates to an anti-inflammatory and anti-bacterial viable hydrogel-based wound dressing containing essential oil and beneficial probiotic metabolites and carrying oxygen for use in chronic wound treatments, and to a production method of said wound dressing. The invention comprises perfluorocarbon (oxygen-carrying structure), herbal and volatile essential oil (anti-inflammatory and anti-bacterial structure) and probiotic (pH-dependent metabolitereleasing structure) encapsulated with organosilica and polymer for long-term and controlled co-distribution of oxygen, essential oil and pH-dependent probiotic metabolite within the same biomaterial.
[0036] In an exemplary embodiment of the invention, the hydrogel-based wound dressing comprises:
[0037] • perfluorocarbon-based oxygen carrier periodic mesoporous organosilica (PMOF), • essential oil,
[0038] • gelatin methacrylate (GelMA),
[0039] • alginate,
[0040] • a probiotic encapsulated with organosilica and alginate polymer.
[0041] In a more detailed embodiment of the invention, said wound dressing comprises:
[0042] « perfluorocarbon-based oxygen carrier periodic mesoporous organosilica (PMOF) in the range of 0.01-0.1 wt. %,
[0043] • essential oil in the range of 5-10 wt. %,
[0044] • gelatin methacrylate (GelMA) in the range of 60-90 wt. %,
[0045] • alginate in the range of 3-7 wt. %,
[0046] • a probiotic encapsulated with organosilica and alginate polymer in the range of 0.51 - 1.1 wt. %.
[0047] In the probiotic encapsulated with organosilica and alginate polymer contained in the wound dressing subject to the invention, the said probiotic releases lactic acid, while the positively charged periodic mesoporous organosilica carries lactose, meaning nutrients for the probiotic. This probiotic encapsulated with organosilica and alginate polymer contains organosilica in the range of 0.01-0.1 wt. % and alginate polymer in the range of 0.5-1 wt. %.In another embodiment of the invention, said wound dressing comprises:
[0048] « perfluorocarbon-based oxygen carrier periodic mesoporous organosilica (PMOF) at a rate of 0.1 wt. %,
[0049] • essential oil at a rate of 10 wt. %,
[0050] • gelatin methacrylate (GelMA) at 81.8 wt. %,
[0051] • alginate at a rate of 7 wt. %,
[0052] • a probiotic encapsulated with organosilica and alginate polymer at 1.1 wt. %.
[0053] In an exemplary embodiment, the probiotic encapsulated with said organosilica and alginate polymer in the wound dressing subject to the invention contains organosilica in the range of 0.1 wt. % and alginate polymer in the range of 1 wt. %.
[0054] In the wound dressing subject to the invention, gelatin methacrylate is dissolved in PBS (phosphate buffered saline) and used as a solution. The amount of GelMA in PBS is 12 wt. % w / v. The wt. % used here is defined as % w / v, i.e., the weight percentages of the components in GelMA solution dissolved in PBS.
[0055] In various embodiments of the hydrogel-based wound dressing subject to the invention, it may contain PMOF, essential oil, GelM A, alginate, and probiotic components encapsulated in an organosilica and alginate polymer, either individually or in combination, in predetermined weight ratios. The fact that the wound dressing contains components in specified weight ratios in the invention was discovered as a result of the work carried out within the scope of the invention.
[0056] The essential oil used in the wound dressing subject to the invention is tea tree oil and / or lavender oil and / or thyme oil and / or peppermint oil and / or cinnamon oil and / or St. John's wort oil. Said essential oils are vegetable and volatile oils with anti-inflammatory and anti-bacterial properties. Thus, the advanced technical effect is achieved due to its antioxidant, anti-bacterial, and anti-inflammatory properties.
[0057] In the probiotic encapsulated with organosilica and alginate polymer mentioned in the invention, lactose and lactic acid bacteria are used. In an exemplary embodiment of theinvention, said lactic acid bacteria are Lactobacillus bacteria; however, the embodiment is not limited thereto.
[0058] The invention relates to a production method of a hydrogel-based wound dressing and comprises the following process steps:
[0059] i. synthesizing perfluorocarbon-based oxygen carrier periodic mesoporous organosilica (PMOF),
[0060] ii. separately dissolving cetyltrimethyl ammonium bromide (CT AB) in a solution containing water, ethanol and ammonia and adding 1,2-bis(trimethoxysilyl)ethane (BTME) and APTES and mixing,
[0061] iii. stirring the mixture in an ethanol solution containing hydrochloric acid solution and then centrifuging, washing with ethanol and drying,
[0062] iv. Adding lactose to the dried mixture, mixing, centrifuging after mixing, and drying, v. coating lactic acid bacteria with the dried mixture,
[0063] vi. adding alginate after coating and adding the final mixture dropwise with a needle into a solution of calcium chloride (CaCl₂),
[0064] vii. separately synthesizing gelatin methacrylate (GelMA),
[0065] viii. mixing gelatin methacrylate with phosphate buffered saline (PBS) solution containing eosin Y, triethanolamine (TEA), and vinyl caprolactam (VC), ix. mixing the mixture with probiotics encapsulated with perfluorocarbon-based oxygen carrier periodic mesoporous organosilica (PMOF) obtained in process step (i.) and porous organosilica and alginate polymer (CAP) obtained in process step (vi.) and adding alginate therein,
[0066] x. adding essential oil to the obtained mixture,
[0067] xi. cross-linking the mixture using visible light and calcium chloride (CaCl2).
[0068] In the process step (i.) of the method steps subject to the invention, perfluorocarbon-based oxygen carrier periodic mesoporous organosilica (PMOF) is synthesized. In the synthesis steps, firstly, cetyltrimethyl ammonium bromide (CTAB) is dissolved in a solution containing water, ethanol, and ammonia. Then, 1,2-bis(trimethoxysilyl)ethane (BTME) and 1H,1H,2H,2H-perfluorooctyltriethoxysilane (POTS) are added into the mixture and stirred. Thus, a CTAB mesoporous template mixture is obtained. Said CTAB template is removed by stirring in an ethanol solution containing hydrochloric acid solution. The resulting mixture is then centrifuged, washed with ethanol, and dried. In an exemplary embodiment of the invention,said synthesis steps are as follows in more detail: firstly, 484.5 mg of cetyltrimethyl ammonium bromide (CT AB) is dissolved in a solution containing 90 ml water, 33 ml ethanol and 28 wt. % ammonia. Then 1.27 g BTME and 0.59 g POTS are added to the mixture and the final mixture is stirred for 48 hours at room temperature. Thus, a CTAB mesoporous template mixture is obtained. Said template is removed by stirring for 6 hours at a temperature of 50°C in 50 ml ethanol solution containing 36 wt. % aqueous hydrochloric acid solution. The resulting solid mixture is then centrifuged, washed 1-2 times with ethanol, and dried in a vacuum at 60°C.
[0069] The expression "separately" mentioned in process step (ii.) of the method steps subject to the invention should be understood as "in a separate place", "in a separate manner" or "in a separate container". In said step, 484.5 mg of cetyl trimethyl ammonium bromide (CTAB) is dissolved in a solution containing 90 mL of water, 33 mL of ethanol, and 28 wt. % ammonia. Then 1.27 g BTME and 0,59 g APTES are added into the mixture. The final mixture is then stirred at room temperature for 48 hours. Said 28 wt. % ammonia content is 0.075 grams in an embodiment of the invention.
[0070] In the process step (iii) of the method steps subject to the invention, the mixture is stirred for 6 hours at 50°C in 50 mL of an ethanol solution containing 36 wt. % or 1.5 g, of aqueous HC1 solution, and the CTAB template is removed. The PMO-NH2 solid obtained after the mixing process is centrifuged, washed 1-2 times with ethanol, and dried under vacuum at 60 °C. In one embodiment of the invention, with said steps, 350 mg of PMO-NH2 is obtained.
[0071] In process step (iv.) of the method subject to the invention, 100 mg of the dried mixture (PMO-NH2) and 30 mg of Lactose dissolved in 1 ml of water are mixed at room temperature for 1 day. This results in a final mixture of Lac-PMO-NH2. After the mixing process, the mixture was centrifuged at 6000 rpm for 15 minutes and dried at room temperature for 24 hours.
[0072] The dried mixture (LacPMO-NH2) in said process step (v.) of the method steps subject to the invention is firstly subjected to sonication in PBS. In an exemplary embodiment of the invention, 1 mg of the dried mixture is subjected to sonication in 1 ml of PBS. In an exemplary embodiment of the invention, the lactic acid bacteria mentioned in said process step are Lactobacillus bacteria, however the embodiment is not limited thereto. After the sonication process, 3×105CFU / mL Lactobacillus bacteria are added to the mixture and mixed. With saidmixing process, the negatively charged surface of the Lactobacillus bacteria is electrostatically coated with the positively charged dried mixture (LacPM0-NH2).
[0073] 10 mg / mL of alginate is added to the mixture prepared in the process step (vi) of the method steps subject to the invention, and it is then added dropwise to a 0.1 M CaC12 solution using a 0.3 mm needle. With said processes, probiotics encapsulated with porous organosilica (LacPMO-NH2) and alginate polymer (CAP) are obtained.
[0074] The expression “in a separate location” mentioned in the process step (vii) of the method steps subject to the invention should be understood to mean “separately” or “in a separate container.” The GelMA mentioned in said process step is synthesized by known methods in accordance with the literature. For said synthesis, gelatin (20 g) is first dissolved in PBS (600 mL) at 60°C for 1 hour with stirring. Then, methacrylic anhydride (16 mL) is added dropwise to the mixture and stirred continuously. The entire mixture is then transferred to a dialysis membrane (12-14 kDa) and kept in autoclaved deionized water at a temperature of 50°C for 7 days to remove unreacted methacrylic anhydride. Water is replaced daily with fresh, preheated water. After 7 days, the obtained solution is filtered through a vacuum filter (110 mm pore size) and then lyophilized to obtain a dried GelMA foam. The mentioned lyophilization process lasts for 1 day at a temperature of (-60)°C. With said processes, GelMA that can be cross-linked with visible light is obtained.
[0075] In the process step (viii) of the method steps subject to the invention, 1 g or 10 wt. % (w / v) of lyophilized gelatin methacrylate is mixed with a 10 mL PBS solution containing eosin Y at a concentration of 0.1 mM as a photoinitiator, 133 pL or 1.3 wt. % w / v TEA as a co-initiator, and 0.1 g or 1.0 wt. % w / v VC as a co-monomer. The mixture obtained after mixing is kept at a temperature of 80°C for 10 minutes.
[0076] In an exemplary embodiment of the process step (ix.) of the method steps subject to the invention, the 1 ml mixture in said step and 1 mg PMOF obtained by process step (i.) are mixed and subjected to sonication for 10 minutes. In an exemplary embodiment of the invention, PMOF is mixed in the range of 0.01-0.1 wt. %. In another exemplary embodiment, PMOF is mixed at 0.1 wt. %. It is then mixed with the probiotics encapsulated (CAP) encapsulated with the porous organosilica (LakPMO-NH2) obtained in the process step (vi) and the alginate polymer. After the mixing process, the alginate is homogeneously added to said suspension.In process step (x.) of the method steps subject to the invention, essential oil at 10 wt. % w / v is added to said mixture. The essential oils mentioned here are tea tree oil and / or lavender oil and / or thyme oil and / or peppermint oil and / or cinnamon oil and / or St. John's wort oil, however the embodiment is not limited thereto.
[0077] In the process step (xi) of the method steps subject to the invention, the mixture to which essential oil has been added is cross-linked by using visible light at 450-550 nm with an intensity of 100 mW / cm2at room temperature for 1-2 minutes, followed with calcium chloride (CaCh) at a concentration of 0.1 M for 15 minutes.
[0078] The room temperatures mentioned in the method steps subject to the invention should be accepted in the temperature range of 20-24°C. The method steps in the invention is used to produce a hydrogel-based viable wound dressing. Various experimental studies have been conducted on the hydrogel-based wound dressing subject to the invention. First of all, the mixtures used in the experimental studies are represented as Mixture 1: alginate (hydrogel), Mixture 2: hydrogel with tea tree oil, Mixture 3: hydrogel containing nanoparticle containing oxygen transport unit (PMOF), Mixture 4: system combining tea tree oil and nanoparticle containing the oxygen carrying unit (PMOF) in the same hydrogel (Alg- Alginate), Mixture 5: only tea tree oil.
[0079] Referring to Figure 1, the oil release amounts of Mixture 2 and Mixture 4 are compared. Mixture 4 can release about 5% more oil compared to Mixture 2. Both mixtures can release tea tree oil into the environment slowly and over a long period of time. This shows that PMOF can adsorb and release more oil over time with its large surface area. Figure 2 compares the amount of oxygen release. Referring to said Figure, Mixture 3, which contains the oxygen carrying unit, releases oxygen continuously and for a longer period of time under hypoxic (1% O2) conditions compared to Mixture 1. The oxygen level of Mixture 3 increased continuously during the 15- day period and after 15 days of incubation, the oxygen level of the medium containing Mixture 3 was approximately 11.5%. These results show that PMOF, the oxygen-carrying nanomaterial, can provide continuous and slow oxygen release from the alginate web to the medium.
[0080] Other cell experiments for the invention were performed using healthy human primary dermal fibroblast cells. In the presence of Mixture 1, Mixture 2, Mixture 3, Mixture 4 and Mixture 5, it was carried out under hypoxic conditions at 37°C for 5 days. Cells in the culture plate wereused as controls. While a decrease in fibroblast cell viability was observed in the presence of Mixture 5 and Mixture 2, cell viability in Mixture 4 remained as in the control group. This result, shown in Figure 3, indicates that cell viability was maintained in hypoxic medium with the use of oxygen and tea tree oil alone, and that tea tree oil and oxygen had no toxic effect on cell viability for 5 days.
[0081] Further, Mixture 2 and Mixture 4 were also exposed to E. coli and S. aureus bacteria for 24 hours. The graph showing the relevant results is shown in Figure 4 and Figure 5. These results showed that tea tree oil at low concentrations (0 pl and 3 pl) was not effective in inhibiting E. coli and S. Aureus bacteria. At these concentrations, an increase in the viability of E. coll in Mixture 2 and Mixture 4 was observed compared to the control (plate). Additionally, the fact that Mixture 4 is more effective than Mixture 2 indicates that PMOF's oxygen release can produce reactive oxygen species, an additional parameter that acts as an antibacterial agent to inhibit bacterial growth, but is not sufficient on its own to inhibit bacteria. It is therefore necessary to use Mixture 2 in combination with tea tree oil to ensure effective inhibition of bacteria (synergistic effect: the combination of tea tree oil and oxygen release) With said study, it was found that the most effective concentration of tea tree oil was 5 pl and that completely inhibited E. coli and S. aureus bacteria in an interaction duration of 24 hours.
[0082] In another study for the hydrogel-based wound dressing subject to the invention, the negatively charged surfaces of probiotics were coated with positively charged porous organosilica nanomaterials and encapsulated with negatively charged alginate polymer (algae / hydrogel). Furthermore, the pores of the organosilica nanomaterials were loaded with Lactose, a nutrient source for probiotics, andLacPMO-NH2in short was obtained. The mixtures used in said studies are represented as Mixture A: Coating withLacPMO-NH2, Mixture B: Algae / LacPMO-NH2(LacPMO-NH2encapsulated with alginate), Mixture C: Encapsulation with Algae / LacPMO-NH2in tea tree oil medium, Mixture D: probiotics control group, Mixture E: gelatin methacrylate (GelMA) and Mixture F: wound dressing (GelMA-CAP) subject to the invention.
[0083] The pH-dependent lactic acid release of probiotics (CAP) coated withLacPMO-NH2and encapsulated with Algae (Mixture B) is shown in Figure 6. CFU and lactic acid release tests were performed to determine whether Mixture A and Mixture B had a toxic effect on probiotics. CFU (colony forming unit) test results show that Mixture B preserves probiotics better than Mixture A and increases probiotic viability. Said results are shown in Figure 7. Figure 8represents a graph showing the lactic acid release of Mixture A and Mixture B over 7 days. As can be seen in Figure 8, the lactic acid release assay, which is a proof of probiotic viability and bioactivity, confirms that Mixture B preserves probiotics better than Mixture A and increases probiotic viability.
[0084] CFU and lactic acid release tests were performed to determine whether Mixture C and Mixture D had a toxic effect on probiotics. CFU test results show that Mixture C preserves probiotics better than Mixture D and increases probiotic viability. Said results are shown in Figure 9. Figure 10 represents the rate of lactic acid released in the medium of Mixture C and Mixture D. As can be seen in said Figure, the lactic acid release assay, which is a proof of probiotic viability and bioactivity, confirms that Mixture C preserves probiotics better than Mixture D. Probiotics (CAP) encapsulated in the prepared hydrogel (algae / alginate) were then added to oxygen¬ releasing hydrogels (GelMA containing PMOF) and experiments with healthy (fibroblast) and cancer (Malme-3M) cells under hypoxic conditions showed that GeLMA in the presence of CAP promoted healthy cell viability while reducing cancer cell viability. These results (Control, Mixture E and Mixture F) and the synergistic effect obtained by co-release of oxygen and probiotic metabolite are shown in Figure 11.
[0085] The above embodiments are intended only to describe the technical concept and features of the present invention, and the purpose of the present invention is to ensure that those skilled in the ait understand the content of the present invention and practice the present invention, and the scope of the present invention is not limited thereto. Equivalent changes or modifications made in accordance with the spirit of the invention are intended to be included in the scope of the invention.
[0086] In an embodiment of the invention that can be used in combination with other embodiments, all parameters mentioned in the process steps can be used, albeit separately.
[0087] Industrial Applicability of the Invention
[0088] The invention relates to an anti-inflammatory and anti-bacterial viable hydrogel-based wound dressing containing essential oil and beneficial probiotic metabolites and carrying oxygen for use in chronic wound treatments and to a production method of said wound dressing, and is industrially applicable.The invention is not limited to the example embodiments above, and the person skilled in the art can readily present other different embodiments of the invention. These should be considered within the protection scope of the invention claimed by the claims.
Claims
CLAIMS1. A hydrogel-based wound dressing, characterized in that it comprises probiotics encapsulated with:• perfluorocarbon-based oxygen carrier periodic mesoporous organosilica (PMOF), • essential oil,• gelatin methacrylate (GelMA),• alginate,• organosilica and alginate polymer.
2. The wound dressing according to claim 1, characterized in that it comprises probiotics encapsulated with:® perfluorocarbon-based oxygen carrier periodic mesoporous organosilica (PMOF) in the range of 0.01-0.1 wt. %,• essential oil in the range of 5-10 wt. %,• gelatin methacrylate (GelMA) in the range of 60-90 wt. %,• alginate in the range of 3-7 wt. %,• organosilica and alginate polymer in the range of 0.51 - 1.1 wt. %.
3. The wound dressing according to claim 2, characterized in that it comprises probiotics encapsulated with:® perfluorocarbon-based oxygen carrier periodic mesoporous organosilica (PMOF) at a rate of 0.1 wt. %,• essential oil at a rate of 10 wt. %,• gelatin methacrylate (GelMA) at 81.8 wt. %,• alginate at a rate of 7 wt. %,• organosilica and alginate polymer at 1.1 wt. %.
4. The wound dressing according to any one of claims 1-3, characterized in that said probiotic encapsulated with organosilica and alginate polymer comprises organosilica in the range of 0.01-0.1 wt. % and alginate polymer in the range of 0.5-1 wt. %.
5. The wound dressing according to claim 4, characterized in that said probiotic encapsulated with organosilica and alginate polymer comprises organosilica in the range of 0.1 wt. % and alginate polymer in the range of 1 wt%.
6. The wound dressing according to any one of claims 1-3, characterized in that said essential oil is tea tree oil and / or lavender oil and / or thyme oil and / or peppermint oil and / or cinnamon oil and / or St. John's wort oil.
7. The production method of hydrogel-based wound dressing, characterized in that it comprises the process steps of:i. synthesizing perfluorocarbon-based oxygen carrier periodic mesoporous organosilica (PMOF),ii. separately dissolving cetyltrimethyl ammonium bromide (CT AB) in a solution containing water, ethanol and ammonia and adding 1,2-bis(trimethoxysilyl)ethane (BTME) and APTES and mixing,iii. stirring the mixture in an ethanol solution containing hydrochloric acid solution and then centrifuging, washing with ethanol and drying,iv. Adding lactose to the dried mixture, mixing, centrifuging after mixing, and drying, v. coating lactic acid bacteria with the dried mixture,vi. adding alginate after coating and adding the final mixture dropwise with a needle into a solution of calcium chloride (CaCl₂),vii. separately synthesizing gelatin methacrylate (GelMA),viii. mixing gelatin methacrylate with phosphate buffered saline (PBS) solution containing eosin Y, triethanolamine (TEA), and vinyl caprolactam (VC), ix. mixing the mixture with probiotics encapsulated with perfluorocarbon-based oxygen carrier periodic mesoporous organosilica (PMOF) obtained in process step (i.) and porous organosilica and alginate polymer (CAP) obtained in process step (vi.) and adding alginate therein,x. adding essential oil to the obtained mixture,xi. cross-linking the mixture using visible light and calcium chloride (CaCl2)8. The production method according to claim 7, characterized in that said mixture in the process step (iii) is stirred for 6 hours at 50°C in 50 mL of an ethanol solution containing an aqueous HCl solution in the range of 36 wt. % or at 1.5 g.
9. The production method according to claim 7, characterized in that 100 mg of said dried mixture in the process step (iv.) and 30 mg of Lactose dissolved in 1 ml of water are mixed for 1 day.
10. The production method according to claim 9, characterized in that after said mixing in the process step (iv.), the mixture is centrifuged at 6000 rpm speed for 15 minutes and dried at room temperature for 24 hours.
11. The production method according to claim 7, characterized in that said dried mixture in the process step (v.) is first subjected to a sonication process in PBS.
12. The production method according to claim 11, characterized in that said lactic acid bacteria in the process step (v.) is Lactobacillus bacteria.
13. The production method according to claim 12, characterized in that in the process step (v.) the negatively charged surface of 3x105CFU / mL Lactobacillus bacteria is coated with the positively charged dried mixture.
14. The production method according to claim 7, characterized in that 10 mg / mL of alginate is added to said mixture in the process step (vi.) and the mixture is added dropwise with a 0.3 mm diameter needle to a CaCl2solution of 0.1 M concentration.
15. The production method according to Claim 7, characterized in that, in the process step (viii), 1 g or 10 wt. % (w / v) of lyophilized gelatin methacrylate is mixed with a 10 mL PBS solution containing eosin Y at a concentration of 0.1 mM as a photoinitiator, 133 pL or 1.3 wt. % w / v TEA as a co-initiator, and 0.1 g or 1.0 wt. % w / v VC as a co-monomer.
16. The production method according to claim 15, characterized in that the mixture obtained after said mixing in the process step (viii) is held at a temperature of 80 °C for 10 minutes.
17. The production method according to claim 7, characterized in that said mixture in the process step (ix.) is mixed with perfluorocarbon-based oxygen carrier periodic mesoporous organosilica (PMOF) obtained in the process step (i.) in the range of 0.01-0.1 wt. % and sonicated for 10 minutes.
18. The production method according to claim 7, characterized in that said essential oil in the process step (x) is added to the mixture at 10 wt. % (w / v).
19. The production method according to claim 18, characterized in that said essential oil in the process step (x.) is tea tree oil and / or lavender oil and / or thyme oil and / or peppermint oil and / or cinnamon oil and / or St. John's wort oil.
20. The production method according to claim 7, characterized in that said mixture in the process step (xi.) is cross-linked by using visible light at 450-550 nm with an intensity of 100 mW / cm2for 1-2 minutes, followed by calcium chloride (CaCh) at a concentration of 0.1 M for 15 minutes.
21. The wound dressing produced by a method according to any one of claims 7-20.
22. The wound dressing produced by a method according to any one of claims 7-20 for use in chronic wound treatments.
